Hikma Pharmaceuticals Plc HIK
LSE · United Kingdom · Health Technology
GBp 1,589.00-29.00 (-1.79%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Hikma Pharmaceuticals PLC (Hikma, Group) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in the United States, Europe, and the UK. Hikma has also filed a submission for its epinephrine nasal spray in Canada, with plans to expand filings beyond these markets in due course.
Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in execution and valuation, although they also flag sensitivity to assumptions that could work against the stock if conditions change. As you read on, you will see how to interpret this evolving narrative and what to watch as new research comes...
Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade. The 'buy' rating is unchanged, with the new target implying 24% upside from Tuesday's share...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.